Brief: Humanigen Executes Licensing Agreement For Lenzilumab In Covid-19 With KPM Tech/Telcon RF Pharmaceutical For South Korea And The Philippines
03/11/2020 12:37
Nov 3 (Reuters) - Humanigen Inc HGEN.O :
* HUMANIGEN EXECUTES LICENSING AGREEMENT FOR LENZILUMAB™ IN
COVID-19 WITH KPM TECH/TELCON RF PHARMACEUTICAL FOR SOUTH KOREA
AND THE PHILIPPINES
* HUMANIGEN INC - AGREEMENT PROVIDES HUMANIGEN UP TO US$20
MILLION
IN MILESTONES AND DOUBLE-DIGIT ROYALTIES ON PRODUCT SALES
* HUMANIGEN INC - TELCON AND KPM TECH WILL BE RESPONSIBLE
FOR
GAINING REGULATORY APPROVAL, SUBSEQUENT COMMERCIALIZATION OF
LENZILUMAB IN ITS TERRITORIES
Source text for Eikon: ID:nBw8LsckPa
Further company coverage: HGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telcon RF Pharmaceutical
See all newsBrief: Telcon Rf Pharmaceutical To Conduct Capital Increase Of 28 Billion Won
Brief: Telcon Rf Pharmaceutical Inc To Acquire 10 Billion Won Worth Of Shares In Abion Inc
Brief: Telcon Rf Pharmaceutical To Acquire 16 Billion Won Worth Of Shares In Abion Inc
Brief: Humanigen Executes Licensing Agreement For Lenzilumab In Covid-19 With KPM Tech/Telcon RF Pharmaceutical For South Korea And The Philippines
Brief: Emmaus Life Sciences Announces The Sale Of Its Telcon Rf Pharmaceutical Inc. Shares